A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (> 12 Yrs) Hispanic Subjects With Asthma.
Phase of Trial: Phase III
Latest Information Update: 24 Aug 2012
At a glance
- Drugs Budesonide; Budesonide/formoterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 24 Aug 2012 Last checked against ClinicalTrials.gov record.
- 01 Sep 2011 Results published in the Annals of Allergy, Asthma and Immunology.
- 18 May 2011 Results pertaining to secondary endpoints were presented at the 107th International Conference of the American Thoracic Society.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History